Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "hold" rating reissued by equities research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports.

Several other research analysts also recently commented on OMER. RODMAN&RENSHAW raised shares of Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Omeros in a research note on Thursday, November 14th. StockNews.com raised Omeros from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Finally, Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday, November 14th. They set a "buy" rating and a $9.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

Omeros Price Performance

Shares of Omeros stock traded up $0.07 during trading hours on Thursday, reaching $10.31. The company's stock had a trading volume of 2,506,727 shares, compared to its average volume of 550,411. Omeros has a one year low of $2.61 and a one year high of $13.60. The firm has a 50 day moving average price of $6.96 and a 200-day moving average price of $5.13. The stock has a market cap of $597.46 million, a P/E ratio of -4.46 and a beta of 1.97.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 7,016 shares during the last quarter. MML Investors Services LLC lifted its stake in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 3,000 shares during the period. SPC Financial Inc. purchased a new stake in shares of Omeros during the third quarter valued at $77,000. SG Americas Securities LLC acquired a new position in shares of Omeros in the 3rd quarter valued at $80,000. Finally, AQR Capital Management LLC acquired a new stake in Omeros during the 2nd quarter worth about $105,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.